Despite the slow market thaw in recent years, 18 biotech companies have priced out IPOs through September 2024, but going ...

The biotech, which has been working towards commercial development of its IP since March 2022, is targeting ASX quotation in ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

Relay Therapeutics faces challenges with limited clinical data and high expenses but shows promise with their 4D drug design ...

We recently compiled a list of the 10 Best Up and Coming Stocks To Buy According to Analysts. In this article, we are going ...

The initial public offering (IPO) of Onyx Biotec Limited ended on Monday, November 18, with a strong subscription, fuelled by ...

Onyx Biotec reported a profit-after-tax of Rs 1.3 crore for the June quarter, with revenue for Q1 FY25 totalling Rs 10.54 ...

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and ...